Competitor Analysis: Her2 and Her3 Receptor Antagonists
Product description
The present Competitive Intelligence Report about Her2 and Her3 receptor antagonists provides a competitor evaluation in the field of Her2 (ErbB2) and Her3 receptor targeting molecules for treatment of cancer as of September 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab) and the development of resistance to trastuzumab treatment has spurred the discovery and development of efficacy enhanced versions of anti-Her2 antibodies or antibodies binding to an epitope different from that of trastuzumab. Other approaches include the development of therapeutic vaccines to specifically stimulate the immune system against Her2 positive cancer cells. Her2 receptor tyrosine kinase inhibitors with a broader target profile including other members of the Her receptor family or including other targets are also in development.
The report includes a compilation of current active projects in research and development of molecules targeting the Her2 (ErbB2) and Her3 receptor. In addition, the report lists company-specific R&D pipelines of Her2 and Her3 receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Her2 and Her3 receptor antagonists provides a competitor evaluation in the field of Her2 (ErbB2) and Her3 receptor targeting molecules for treatment of cancer as of September 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab) and the development of resistance to trastuzumab treatment has spurred the discovery and development of efficacy enhanced versions of anti-Her2 antibodies or antibodies binding to an epitope different from that of trastuzumab. Other approaches include the development of therapeutic vaccines to specifically stimulate the immune system against Her2 positive cancer cells. Her2 receptor tyrosine kinase inhibitors with a broader target profile including other members of the Her receptor family or including other targets are also in development.
The report includes a compilation of current active projects in research and development of molecules targeting the Her2 (ErbB2) and Her3 receptor. In addition, the report lists company-specific R&D pipelines of Her2 and Her3 receptor targeting molecular entities. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
- Therapeutic Her2 Vaccines
- Herceptin Pipeline
- Trastuzumab emtansine Pipeline
- Selective Her2 Receptor Antagonists (incl. Biosimilars & Biobetters)
- Selective Her3 Receptor Antagonists
- Dual- or Multi-Target Her2 Receptor Antagonists
- Dual- or Multi-Target Her3 Receptor Antagonists
- Pan-Her Receptor Antagonists
- Corporate Her2 and Her3 Receptor Antagonist R&D Pipelines
- About La Merie
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
